Evidence map›Paper›PMID 28212684›Full record

ArticleOrphanet journal of rare diseases2017

The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry.

L Villeneuve, G Passot, O Glehen, S Isaac, F Bibeau, P Rousset, F N Gilly, RENAPE Network

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02834169 (French National Registry of Rare Peritoneal Surface Malignancies), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02834169 unknown statusnot on this map

French National Registry of Rare Peritoneal Surface Malignancies (RENAPE Registry)

Typeobservational_patient_registrySponsorHospices Civils de LyonRan2010 to 2018Enrolled2,171ConditionsRare Peritoneal Surface Malignancies, Pseudomyxoma Peritonei, Peritoneal Mesothelioma, Desmoplastic Small Round Cell TumorArmsNon interventional
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Advances in the management of peritoneal malignancies.Nature reviews. Clinical oncology · 2022
    Review
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Observational
  18. The Current Status of Peritoneal Surface Oncology in India.Indian journal of surgical oncology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

L VilleneuveHospices Civils de Lyon, Pôle Information Médicale Evaluation Recherche, Unité de Recherche Clinique, Lyon, France. laurent.villeneuve@chu-lyon.fr.
G PassotEMR 3738, Lyon 1 University, Lyon, France.
O GlehenEMR 3738, Lyon 1 University, Lyon, France.
S IsaacEMR 3738, Lyon 1 University, Lyon, France.
F BibeauDepartment of Pathology, Centre Hospitalier Universitaire, Caen, France.
P RoussetEMR 3738, Lyon 1 University, Lyon, France.
F N GillyEMR 3738, Lyon 1 University, Lyon, France.
RENAPE Network
Université Claude Bernard Lyon 1 · FRCentre Hospitalier Universitaire de Caen Normandie · FRHospices Civils de Lyon · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRare peritoneal cancers represent complex clinical situations requiring a specific and multidisciplinary management. Because of their rarity, lack of awareness and knowledge often leads to diagnostic delays and misdiagnosis. And patients are not systematically referred to expert centers as they should be. Clinicians and researchers also face unique challenges with these rare cancers, because it is hard to conduct adequately powered, controlled trials in such small patient population. This is how an observational patient registry constitutes a key instrument for the development of epidemiological and clinical research in the field of these rare cancers. It is the appropriate tool to pool scarce data for epidemiological research and to assess the impact of diagnostic and therapeutic strategies. We aimed to provide the outlines and the framework of the RENAPE observational registry and share our experience in the establishment of a national patient registry.

resultsThe RENAPE observational registry has been launched in 2010 thanks to institutional supports. It concerns only patients with a histological diagnosis confirming a peritoneal surface malignancy. A web secured clinical database has been implemented based on data management procedures according to the principles of international recommendations and regulatory statements. A virtual tumor bank is linked in order to the conduct translational studies. Specialized working groups have been established to continuously upgrade and evolve the common clinical and histological data elements following the last classifications and clinical practices. They contribute also to standardize clinical assessment and homogenize practices.

conclusionsThe RENAPE Registry may improve awareness and understanding of the rare peritoneal tumors into the incidence, prevalence, recurrence, survival and mortality rates, as well as treatment practices thereby enabling therapeutic intervention to be evaluated and ultimately optimized.

trial registrationClinicalTrials.gov Identifier: NCT02834169.

Indexed as

RegistriesFemaleFranceHumansMaleNational Health ProgramsPeritoneal NeoplasmsRare DiseasesPatient registryPeritoneal mesotheliomaPseudomyxoma peritoneiRare cancer networkRare peritoneal tumor

Identifiers

PMID28212684
PMCPMC5316145
OpenAlexW2588664294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.